Table 3.

Multivariate analysis of clinical predictors of biochemical progression after immediate radical prostatectomy in patients who would have met the criteria for active monitoring.

a) Patel criteria (Clinically localized, Gleason score ≤ 7, and no significant comorbidities)
	HR	95% CI	p-value
Age (yrs)	1.01	1.00–1.02	0.17
PSA (ng/ml)	1.04	1.03–1.04	<0.0001
Gleason > 6	2.74	2.27–3.32	<0.0001
Clinical Stage T2 vs. T1	1.89	1.56–2.30	<0.0001

b) Choo criteria (T1b-T2b N0M0, Gleason score ≤ 7, and PSA ≤ 15 ng/ml
	HR	95% CI	p-value
Age (yrs)	1.00	0.99–1.02	0.68
PSA (ng/ml)	1.15	1.12–1.19	<0.0001
Gleason > 6	2.87	2.30–3.58	<0.0001
Clinical Stage T2 vs. T1	1.92	1.55–2.38	<0.0001

c) Mohler criteria (T1c PCa)
	HR	95% CI	p-value
Age (yrs)	1.01	0.99–1.03	0.44
PSA (ng/ml)	1.06	1.04–1.07	<0.0001
Gleason > 6	3.19	2.35–4.35	<0.0001